EZH2 and lymphoma: The IGF axis has been implicated in acquired drug resistance in various hematologic cancers, and selective IGF-1 receptor inhibitors could block tumor cell proliferation and migration and overcome resistance to treatment of multiple myeloma, and lymphomas with bortezomib, EZH2 inhibitors and crizotinib 66–68.